A Phase I study to Evaluate the Tolerability, Safety, and Immunogenicity of a PIKA-Adjuvanted Recombinant SARS-CoV-2 Spike (S) Protein Subunit Vaccine in Healthy Adults

计划入组 90 人

CORVax12: SARS-CoV-2 Spike (S) Protein Plasmid DNA Vaccine Trial for COVID-19 (SARS-CoV-2)

计划入组 16 人 · 首次发布于 2020 年 11 月 13 日

Phase III Clinical Trial of CinnaGen COVID-19 Vaccine (SpikoGen)

计划入组 16,876 人 · 首次发布于 2021 年 8 月 13 日

Avacc-10

Plant-based virus-like particles, recombinant, adjuvanted COVID-19 vaccine

Nuvaxovid

Protein Sciences Corporation

United States

ALIFE HEALTH S A S

Colombia

HOUSE OF SUPPLEMENTS AUSTRALIA PTY LTD

Australia

Blue Lake and CyanVac's Intranasal COVID-19 Vaccine Shows Promise in Phase 2a Trial

CyanVac's Intranasal COVID-19 Vaccine Candidate, CVXGA, Enters Phase 2b Trial

Capricor Therapeutics Initiates First-in-Human Trial of StealthX Exosome-Based Vaccine Platform